3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Neuroblastoma
9
Melanoma
4
Ganglioneuroblastoma
4
Triple Negative Breast Neoplasms
3
Lung Neoplasms
3
Carcinoma, Non-Small-Cell Lung
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Transplant-Related Hematologic Malignancy
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Hodgkin Disease
1
Gliosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Carcinosarcoma
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
34
Cisplatin
29
Paclitaxel
15
Brachytherapy
15
Radiotherapy
14
Carboplatin
14
Bevacizumab
14
Blood Specimen Collection
13
Specimen Handling
12
Magnetic Resonance Spectroscopy
11
Colposcopy
11
Nivolumab
10
Drug Therapy
10
atezolizumab
8
Human Papillomavirus DNA Tests
8
Gemcitabine
8
lenvatinib
7
Radiation
6
Platinum
6
Biopsy
6
toripalimab
5
cemiplimab
5
Surveys and Questionnaires
5
Standard of Care
5
Radiotherapy, Intensity-Modulated
5
Practice Guidelines as Topic
5
Patient Navigation
5
Fulvestrant
5
Fluorodeoxyglucose F18
5
zimberelimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Cervical Neoplasms
×
sargramostim
×
1 year
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled